• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Generex Biotechnology Announces Acquisition of Surgical Device Manufacturer

Share:

January 14, 2019

Pantheon Medical manufactures a line of FDA cleared products used in orthopedic surgeries including screws, plates, implants, and anchors

Generex Biotechnology Corporation is pleased to announce that the company has entered into a letter of intent to acquire Pantheon Medical – Foot & Ankle, a manufacturer of specialty orthopedic surgery products and tools. Under the terms of the deal, Generex will acquire all of the assets of Pantheon Medical including business operations, accounts receivable and inventory, contracts, and an FDA letter related to balanced plating system, on a debt free basis, for One Million Four Hundred Thousand Dollars ($1,400,000) worth of Generex stock, plus additional cash and stock consideration upon achieving certain sales and profit goals.

Pantheon Medical – Foot & Ankle is a multi-million dollar company that began operations in 2014 with a physician friendly, “all-in-one,” integrated kit that includes plates, screws, and tools required for orthopedic surgeons and podiatrists conducting foot and ankle surgeries. Over the next three years, the Company will be developing and submitting several new product lines to the FDA which will include cannulated surgical screws and surgical staples, as well as a proprietary Hammertoe System.

Travis H. Bird, CEO of Pantheon Medical, commented on the deal, “Partnering with Generex will enable us to expedite Pantheon’s ability to build a manufacturing company with proprietary product lines that offer convenience and cost effectiveness to physicians. We are already seeing significant uptake in the marketplace with our ‘one stop shop’ approach to orthopedic surgery, and the new product lines will expand our market reach.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“The acquisition of Pantheon expands the commercial product portfolio of Generex into the surgical field, adding revenues and profits with their current product line and significant upside opportunities for new FDA-approved product introductions over the next several years,” stated Joe Moscato, CEO of Generex. “Our MSO partners, many of whom are orthopedic surgeons and podiatrists, will immediately benefit from Pantheon’s Foot & Ankle surgery kit. The acquisition demonstrates Generex’s commitment to providing end-to-end solutions that enhance physician’s practice and improve outcomes for patients. We are in the process of completing the due diligence on the Pantheon acquisition, with plans to close the transaction in the coming weeks.”

Date: January 14, 2019

Source: Yahoo Finance

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Worst Deal Ever? Bayer’s Market Cap Now Close To The Total Cost It Paid For Monsanto
  • ‘Data is king’ — HealthReveal Founder on why Market is Ripe for Integration-Focused Startups‘Data is king’ — HealthReveal Founder on why Market is Ripe for Integration-Focused Startups
  • Nexelis to Acquire Specialty Immunogenicity and Immune-Oncology Testing Laboratory ImmunXpertsNexelis to Acquire Specialty Immunogenicity and Immune-Oncology Testing Laboratory ImmunXperts
  • Hologic Completes Acquisition of MobidiagHologic Completes Acquisition of Mobidiag
  • Talis Awarded $25M NIH Contract for Point-of-Care COVID-19 TestingTalis Awarded $25M NIH Contract for Point-of-Care COVID-19 Testing
  • Epic Integrates Caris Molecular Testing Portfolio with Epic’s ORA Network
  • One Step Closer: FTC Clears AbbVie and Allergan’s $63 Billion MergerOne Step Closer: FTC Clears AbbVie and Allergan’s $63 Billion Merger
  • Akili’s Video Game Therapy Linked to Reduced Cognitive Impairments in Patients with DepressionAkili’s Video Game Therapy Linked to Reduced Cognitive Impairments in Patients with Depression

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications